DERM

Journey Medical

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

24

Business Summary

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing products for the treatment of dermatological conditions. Its portfolio targets a variety of medical and aesthetic skin issues with prescription therapies.

 


Analyze DERM on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$272

Forward P/E

32.5

PEG

-

PRICE TO SALES

3.2

PRICE TO BOOK

10.5

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.35

Next Year EPS Growth Estimate

$0.25

Next Year Revenue Growth Estimate

53.80%

Return on Equity (ROE)

-33.40%

FREE CASH FLOW

Operating Margin

-16.90%

Debt-to-Equity

1

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze DERM on TradingView

Gainseekers Quantitative Analysis

Summary

Journey Medical currently has a market capitalization of $272 million but is unprofitable, with a negative EPS of -$0.35 and an operating margin of -16.90%. However, the company is projected to achieve significant sales growth of 53.80% and a positive EPS of $0.25 next year. The stock trades at a Price / Sales of 3.2 and has a notable Short % of Float of 11.70%, while institutional ownership stands at 41.00%.

AI Exposure / Tech Reliance

The provided data does not contain any information regarding the company's AI exposure or technology reliance.

The Bull Case

The bull case is driven by expectations of a turnaround, with analysts forecasting 53.80% sales growth and a positive EPS of $0.25 next year. This optimism is supported by a strong consensus rating of 1.5 and a mean consensus target price of $13.50.

The Bear Case

The company is currently unprofitable with a Return on Equity of -33.40% and an Operating Margin of -16.90%. Concerns are compounded by a high Price / Book ratio of 10.5, a Debt / Equity ratio of 1, and a significant Short % of Float at 11.70%.

Market Sentiment & Smart Money

Short Interest %

11.70%

Analyst Consensus

1.5

Average Analyst Price Target

$13.50

Institutional Ownership %

41.00%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.